Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

Inclusion Criteria: * The subject is of legal age to participate in the study per the laws of their respective geography. * The subject has documented paroxysmal, persistent, permanent or long-term/longstanding persistent non-valvular atrial fibrillation (i.e., the subject has not been diagnosed with rheumatic mitral valvular heart disease). * The subject has a calculated CHA2DS2-VASc score of 2 or greater. * The subject is deemed by two study physicians to be unsuitable for oral anticoagulation. * The subject is deemed by a study physician to be suitable for the defined protocol pharmacologic regimen of aspirin and clopidogrel therapy following WATCHMAN Closure Device implant. * The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial. * The subject is able and willing to return for required follow-up visits and examinations. Exclusion Criteria: * The subject is unable or unwilling to return for required follow-up visits and examinations. * The subject had or is planning to have any invasive cardiac procedure within 30 days prior to randomization (e.g., cardioversion, ablation). * The subject is planning to have any cardiac or non-cardiac invasive or surgical procedure that would necessitate stopping or modifying the protocol required medication regimen within 90 days after the WATCHMAN Closure Device implant (e.g., cardioversion, ablation, cataract surgery). * The subject had a prior stroke (of …